The FDA’s real-time clinical trials initiative is important, but not because it creates a new buzzword for interoperability. It matters because it puts pressure on a problem the industry has been dealing with for years, clinical trial data moves too slowly, with too much manual reconciliation. With the industry coming to agreement on the problem, we must ask how we make interoperability work at scale.
The instinctive reaction is understandable: if interoperability is the problem, shouldn’t there be one solution?
Wrong.
Interoperability is not a single workflow problem. It is an ecosystem challenge. Solving it requires focused subject matter expertise that can break down the multitude of operational, technical, regulatory, and data-standardization issues embedded within today’s clinical trial infrastructure.
The industry is not looking for a single solution. It is looking for proficiency, flexibility, and agility.
A successful interoperability strategy will require a combination of agnostic technologies that can work across:
- any site’s source system (including EHRs, eSource, imaging, etc)
- any sponsor’s data capture platform
- any CRO operational workflow
- and now, increasingly, the FDA’s evolving regulatory pipelines
That level of connectivity cannot realistically come from one platform alone.
Clinical Research Is Too Complex for a Closed Ecosystem
Other highly regulated industries have already learned how to move trusted data across fragmented ecosystems. Financial services, for example, depends on many independent institutions, legacy systems, intermediaries, and oversight bodies, yet transactions still move with speed, traceability, and shared rules. Clinical research has a higher evidentiary and patient-safety burden, but that should sharpen the interoperability problem, not excuse the industry from solving it.
In clinical trials, the challenge is not just that sites use different EHRs or sponsors use different EDCs. It is that every handoff has to preserve protocol context, source traceability, data quality, privacy, and regulatory confidence. CRO workflows, labs, imaging vendors, safety platforms, and regulatory systems all add more variation.
There is no universal infrastructure layer underneath clinical research today. That means interoperability cannot simply be installed; it has to be orchestrated across the systems and stakeholders that already exist.
The organizations that will move the industry forward are not necessarily those trying to own the entire workflow. They are the ones that can connect fragmented systems without forcing sites, sponsors, or regulators into rigid technology environments. This is how other industries have solved the complex issues around interoperability, and this is how it will be solved in clinical research.
It’s Time to Accelerate Collaboration, Not Consolidation
One of the most important aspects of the FDA’s real-time clinical trials initiative is the acknowledgment that faster regulatory review depends on better data movement.
This is a positive step for the industry. But it is important that the conversation does not unintentionally evolve into the idea that interoperability can or should be centralized through a single commercial pathway.
No single vendor has universal access to every healthcare system, every sponsor environment, or every regulatory process. And frankly, that is healthy.
Innovation in interoperability has historically come from specialization. Subject matter experts that take a deep dive into solving the complexities of their piece of the larger puzzle:
- Organizations focused on data transfer
- Organizations focused on risk-based quality management
- Organizations focused on patient recruitment
The future is not one company replacing the ecosystem. It is an ecosystem that finally works together.
Agnostic Connectivity Will be a Requirement
As the industry moves toward real-time data exchange, the most valuable capability will not be platform dominance. It will be interoperability agility.
- Can systems adapt to evolving requirements, like the new FDA expectations?
- Can data move cleanly between competing technologies?
- Can integrations scale globally?
- Can sites participate without replacing the systems they already depend on?
Those are the questions that matter.
The winners in this next phase of clinical research infrastructure will be the organizations that reduce friction across the ecosystem, not the ones trying to control it.
Real Interoperability Requires Industry-Wide Participation
The future is not one company owning the entire clinical research workflow. That is not how this industry is built. The more realistic path is a set of interoperable, specialized systems that can move data with quality, traceability, and trust. If the FDA’s initiative helps push the industry in that direction, it will be a meaningful step forward.
No single organization can solve this alone because no single organization owns the problem alone. That is not a weakness of the model. It is the reality of modern, global clinical research. And it is exactly why the industry must approach interoperability as a collaborative capability, not a competitive bottleneck.